Clinical Trials Browser

Phase 3 × INDUSTRY × lazertinib × Clear all

NCT04248829 2026-05-28

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Completed

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-05-08

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung